Skip to main content
OpenTrials
Completed

NCT Number: NCT02377622

Clinical Performance Comparison of 2 THERANOVA 400 Dialyzer Prototypes in HD With High-Flux Dialyzers in HD and hv HDF Mode

The study investigates the performance of a new dialyzer (Theranova 400) containing a membrane with increased pore sizes. The performance will be determined by the removal of middle molecules (with different molecular size) from the blood compartment. Two different Theranova 400 prototypes (AA and BB) operated in hemodialysis mode will be compared with a Cordiax Fx-80 dialyzer, operated in hemodialysis mode, and with a Cordiax Fx-800, operated in high volume hemodiafiltration mode. Safety events and albumin loss into the dialysate will be monitored

Completed

Looking for future studies?

Notify Me

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient has end-stage renal disease (Chronic kidney disease stage 5D)
  • Patient is 18 years of age or older
  • Patient is male or female
  • Patient, if female, is non-pregnant; and if capable of becoming pregnant, will be using a medically acceptable means of contraception during participation in the study 5 .Patient has been receiving HD or HDF therapy for >3 months prior to study enrollment and is expected to survive for at least 12 months after enrollment.
  • Patient has a stable functioning native fistula 7. Patient is willing to comply with the study requirements for therapy during the entire study treatment period 8. Patient is capable fo providing written informed consent to participate in the study

Exclusion criteria

  • Patient is undergoing single-needle dialysis
  • Patient has an known abnormal k/λ ratio (less than 0.37, or greater than 3.1)
  • Patient has a known active infection and is currently receiving antibiotic treatment
  • Patient has known active cancer
  • Patient has a known positive serology test for human immunodeficiency virus (HIV) or hepatitis B,C or E
  • Patient has a known serious hemostasis disorder
  • Patient has a known monoclonal gammopathy
  • Patient has a known polyclonal gammopathy
  • Patient has a unstable condition as judged by the treating physician based on medical history, physical examination and laboratory testing including (but not limited to) any of the following:
  • Myocardial infarction within the last 3 months
  • Tachyarrhythmia or bradyarrhythmia absoluta
  • Unstable angina pectoris
  • Left ventricular ejection fraction <30%
  • Significant pericardial disease
  • Patient has any other known comorbidity that could, in the opinion of the Investigator, potentially conflict with the study purpose or procedure
  • Patient has a known significant psychiatric disorder or mental disability that could interfere with the patient's ability to provide informed consent and/or comply with protocol procedures
  • Patient has a history of non-compliance with the dialysis prescription, as assessed by the Investigator
  • Patient has participated in another interventional clinical study in the past 3 months, or is currently participating in another interventional clinical study

Treatment and study plan

THERANOVA 400 dialyzer prototype AA

Device

THERANOVA 400 dialyzer prototype BB

Device

FX CorDiax 80 dialyzer

Device

FX CorDiax 800 Dialyzer

Device

Primary outcomes

  1. Overall clearance of lambda FLC clearance

    Time frame: Five (5) hours ( for each mid-week dialysis session)

    Blood and dialysate

  2. Overall albumin loss

    Time frame: Five (5) hours (for each mid-week dialysis session)

    Dialysate

Secondary outcomes

  1. Types and frequency of adverse events and device deficiencies as a measure of safety and dialyzer tolerability

    Time frame: Average 60 days (continuously, from signature of informed consent form until 1 week after last hemodialysis session with an experimental or active comparator product)

    All adverse events and device deficiencies will be recorded

  2. Clearance of other middle sized molecules

    Time frame: Five (5) hours (for each mid-week dialysis session)

    Blood and dialysate

  3. Hematology ( blood cell counts; hematocrit and hemoglobin)

    Time frame: Five (5) hours ( for each mid-week dialysis session)

    Blood

Sponsors and collaborators

Lead sponsor

Vantive Health LLC

Industry

Collaborators

  • Baxter Healthcare Corporation

Registry information

Official study title

Comparison of the Clinical Performance of 2 THERANOVA 400 Dialyzer Prototypes in HD With a High-Flux Dialyzer in HD and a High-Flux Dialyzer in hvHDF - A Pilot Study

Important dates

Study start
2015
Primary completion
2015
Study completion
2015
First posted
Mar 3, 2015
Registry last updated
Mar 13, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.